Ubs Group Ag Tyme Technologies, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

Shares

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 10, 2022	BUY	$0.23 - $0.35 $1,053 - $1,603	4,580 Added 19.49%	28,081 $8,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $1,428 - $3,468	5,101 Added 27.72%	23,501 $8,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $11,040 - $19,136	18,400 New	18,400 $11,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $34,429 - $47,992	-34,777 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.14 - $1.87 $25,988 - $42,630	22,797 Added 190.29%	34,777 $44,000
Q1 2021 May 12, 2021	BUY	$1.34 - $3.53 $4,281 - $11,278	3,195 Added 36.37%	11,980 $21,000
Q4 2020 Feb 11, 2021	BUY	$0.87 - $1.26 $7,642 - $11,069	8,785 New	8,785 $11,000
Q3 2020 Nov 12, 2020	SELL	$0.93 - $1.35 $60,839 - $88,315	-65,419 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$0.97 - $1.7 $14,417 - $25,267	-14,863 Reduced 18.51%	65,419 $87,000
Q1 2020 May 01, 2020	SELL	$0.9 - $1.95 $9,313 - $20,178	-10,348 Reduced 11.42%	80,282 $88,000
Q4 2019 Feb 14, 2020	BUY	$1.0 - $1.49 $29,829 - $44,445	29,829 Added 49.06%	90,630 $127,000
Q3 2019 Nov 14, 2019	BUY	$0.97 - $1.77 $35,711 - $65,164	36,816 Added 153.5%	60,801 $73,000
Q2 2019 Aug 14, 2019	BUY	$0.96 - $1.89 $22,929 - $45,142	23,885 Added 23885.0%	23,985 $29,000
Q1 2019 May 14, 2019	SELL	$1.76 - $3.73 $111,548 - $236,407	-63,380 Reduced 99.84%	100 $0
Q4 2018 Feb 14, 2019	BUY	$2.01 - $4.21 $75,240 - $157,592	37,433 Added 143.71%	63,480 $235,000
Q3 2018 Nov 14, 2018	BUY	$2.18 - $3.44 $18,928 - $29,869	8,683 Added 50.01%	26,047 $72,000
Q2 2018 Aug 14, 2018	BUY	$2.05 - $4.09 $10,036 - $20,024	4,896 Added 39.27%	17,364 $54,000
Q1 2018 May 15, 2018	SELL	$2.12 - $7.0 $2,429 - $8,022	-1,146 Reduced 8.42%	12,468 $28,000
Q4 2017 Feb 14, 2018	BUY	$3.25 - $7.3 $44,245 - $99,382	13,614	13,614 $87,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.